(Q45947014)

18 December 2017

title

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. (English)

1 reference

18 December 2017

cost-effectiveness analysis

main subject

osteoporosis

0 references

1 reference

F Borgström

1

1 reference

18 December 2017

O Ström

2

1 reference

18 December 2017

J Coelho

3

1 reference

18 December 2017

H Johansson

4

1 reference

18 December 2017

A Oden

5

1 reference

18 December 2017

E V McCloskey

6

1 reference

18 December 2017

J A Kanis

7

1 reference

18 December 2017

language of work or name

English

0 references

publication date

30 June 2009

1 reference

18 December 2017

Osteoporosis International

published in

1 reference

18 December 2017

volume

21

1 reference

18 December 2017

issue

3

1 reference

18 December 2017

page(s)

495-505

1 reference

18 December 2017

https://scigraph.springernature.com/pub.10.1007/s00198-009-0989-8

exact match

0 references

cites work

Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-009-0989-8

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-009-0989-8

Variations in population health status: results from a United Kingdom national questionnaire survey

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-009-0989-8

Effect and offset of effect of treatments for hip fracture on health outcomes

21 January 2018

1 reference

12 December 2020

Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial

1 reference

12 December 2020

Mortality after osteoporotic fractures

1 reference

12 December 2020

The burden of osteoporotic fractures: a method for setting intervention thresholds

1 reference

12 December 2020

Guidelines for diagnosis and management of osteoporosis

1 reference

12 December 2020

The cost utility of bisphosphonate treatment in established osteoporosis

1 reference

12 December 2020

FRAX and the assessment of fracture probability in men and women from the UK

1 reference

12 December 2020

Treatment of established osteoporosis: a systematic review and cost-utility analysis.

1 reference

12 December 2020

Costs and quality of life associated with osteoporosis-related fractures in Sweden.

1 reference

12 December 2020

At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis.

1 reference

12 December 2020

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX)

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Non-compliance: the Achilles' heel of anti-fracture efficacy

1 reference

12 December 2020

Cost-effectiveness of fracture prevention in established osteoporosis.

1 reference

12 December 2020

Assessment of compliance with osteoporosis treatment and its consequences in a managed care population

1 reference

12 December 2020

An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials.

1 reference

12 December 2020

Epidemiology of fractures in 15,000 adults: the influence of age and gender.

1 reference

12 December 2020

Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden.

1 reference

12 December 2020

Problems with primary care data quality: osteoporosis as an exemplar.

1 reference

12 December 2020

Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden

1 reference

12 December 2020

Lifetime risk of hip fractures is underestimated

1 reference

12 December 2020

Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model

1 reference

12 December 2020

A computer model to analyze the cost-effectiveness of hormone replacement therapy

1 reference

12 December 2020

[Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006]

1 reference

12 December 2020

The risk and burden of vertebral fractures in Sweden

1 reference

12 December 2020

Fracture risk remains reduced one year after discontinuation of risedronate

1 reference

12 December 2020

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

1 reference

12 December 2020

A New Approach to the Development of Assessment Guidelines for Osteoporosis

1 reference

12 December 2020

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.

1 reference

12 December 2020

Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal.

1 reference

12 December 2020

Effects of risedronate on fracture risk in postmenopausal women with osteopenia

1 reference

12 December 2020

Intervention thresholds for osteoporosis in the UK

1 reference

12 December 2020

2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

1 reference

12 December 2020

Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study

1 reference

12 December 2020

Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment

1 reference

12 December 2020

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

1 reference

12 December 2020

The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective

1 reference

12 December 2020

The cost-effectiveness of alendronate in the management of osteoporosis

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

1 reference

12 December 2020

Cost-effective osteoporosis treatment thresholds: the United States perspective

1 reference

12 December 2020

Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women

1 reference

12 December 2020

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

1 reference

12 December 2020

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

1 reference

12 December 2020

Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures

1 reference

12 December 2020

10.1007/S00198-009-0989-8

Identifiers

DOI

1 reference

18 December 2017

Dimensions Publication ID

1052568959

0 references

1 reference

18 December 2017